Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803058 · ClinicalTrials.gov registry record · Phase 2
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
A Phase 2 study of Kidney Transplantation, sponsored by ITB-Med.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT04803058: Active Phase 2 study of Kidney Transplantation, sponsored by ITB-Med.
NCT04803058 is a Phase 2 study of Kidney Transplantation that is active but no longer recruiting, run by ITB-Med. The registered enrollment target is 18 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04803058, a Phase 2 study of Kidney Transplantation, is active but no longer recruiting, sponsored by ITB-Med.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Primary Outcome
The proportion of patients off immunosuppression with good safety and tolerability
Conditions Studied
Interventions
- BIOLOGICAL TCD601
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Other
- Samsung Medical University - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What the registry record for NCT04803058 still lists
NCT04803058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which TCD601 is the first listed.
NCT04803058 reports a single indexed study location in Massachusetts, Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT04803058 about?
NCT04803058 is a clinical study titled "A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)". The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
What is the current status of trial NCT04803058?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-12-14. Estimated completion is 2030-03.
What conditions does trial NCT04803058 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT04803058?
The interventions under investigation include: TCD601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04803058?
This trial is sponsored by ITB-Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04803058 being conducted?
This trial has 3 study locations across Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04803058's enrollment target sits among peer trials
18 31st of 33 higher than 3 of 33 other Kidney Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
-
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
COMPLETED · Phase 2
-
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
COMPLETED · Phase 2
-
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI